Comparison of Aflibercept Versus Ranibizumab in Management of Diabetic Macular Edema (DME)

NCT04087746 Phase 4 COMPLETED

Diabetic macular edema (DME) is a sign of diabetic retinopathy that affects central vision. It is also a leading cause of visual decline in younger patients, especially in developing countries like our Arab community. Intra-vitrreal injection of anti-vascular endothelial growth factor (AVEGF) in management of DME had significant improvement in the final logMAR Un-corrected Distant Visual Acuity ( UCDVA) and logMAR Best Corrected Distant Visual Acuity (BCDVA), as well as reduction in the central retinal thickness from baseline measurement.

Details

Lead sponsor	Minia University
Phase	Phase 4
Status	COMPLETED
Enrolment	400
Start date	2017-01
Completion	2019-06

Conditions

• Diabetic Macular Edema

Interventions

• Aflibercept
• Ranibizumab

Primary outcomes

• measuring the main change in visual acuity — 2 years
  measuring the main change in visual acuity in logarithm of the minimum angle of resolution (log MAR) using projector chart as functional outcome

Countries

Egypt